ReviewCureus2025
Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a well-established risk factor for perioperative morbidity, including periprosthetic joint infection (PJI) and unplanned readmission following total hip and knee arthroplasty. Glucagon-like peptide-1 (GLP-1) receptor agonists induce clinically meaningful weight loss and metabolic optimisation, yet their perioperative influence in arthroplasty populations remains uncertain. In this systematic review and meta-analysis of observational cohorts comprising adults with obesity undergoing primary hip or knee arthroplasty, outcomes were compared between patients receiving perioperative GLP-1 therapy and those not exposed to these agents. Eight cohorts encompassing 95,503 individuals, including 22,098 GLP-1 users, met inclusion criteria. Perioperative GLP-1 therapy was associated with a significantly reduced incidence of PJI after total hip arthroplasty and fewer 90-day hospital readmissions, corresponding to an absolute risk reduction of approximately 1.8% from a median baseline risk of 9% and an estimated number needed to treat of 56. No significant association was demonstrated for PJI following total knee arthroplasty or for revision procedures, and GLP-1 therapy was not linked to increased rates of venous thromboembolism, acute kidney injury, cerebrovascular events, myocardial infarction, or hypoglycaemia. Certainty of evidence was moderate for hip PJI and readmission and low for knee PJI and revision outcomes. These findings suggest that perioperative GLP-1 therapy may confer clinically relevant benefits in selected arthroplasty populations, underscoring the need for well-designed randomised trials to define optimal perioperative protocols, economic value, and long-term implant survivorship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.